IQVIA Holdings Inc. $IQV Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 46,530 shares of the medical research company’s stock, valued at approximately $12,510,000.

A number of other institutional investors also recently made changes to their positions in the company. Korea Investment CORP acquired a new position in IQVIA in the 2nd quarter valued at $13,918,000. Congress Asset Management Co. bought a new stake in IQVIA in the 3rd quarter valued at about $24,560,000. Deutsche Bank AG acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $143,074,000. BlackRock Inc. acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $2,811,292,000. Finally, National Pension Service increased its holdings in shares of IQVIA by 6.6% during the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after purchasing an additional 23,411 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. Royal Bank Of Canada lifted their price target on shares of IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. JPMorgan Chase & Co. increased their price target on IQVIA from $295.00 to $325.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 28th. Mizuho raised their price objective on IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Stifel Nicolaus lifted their price objective on IQVIA from $276.00 to $303.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $294.21.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $262.32 on Wednesday. The company’s 50 day simple moving average is $266.22 and its 200 day simple moving average is $210.59. The stock has a market capitalization of $43.23 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 2.30 and a beta of 1.16. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion during the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company’s quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the company earned $3.00 earnings per share. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.